Compare SXI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | DYN |
|---|---|---|
| Founded | 1955 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1994 | 2020 |
| Metric | SXI | DYN |
|---|---|---|
| Price | $220.50 | $16.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $332.40 | $34.33 |
| AVG Volume (30 Days) | 159.0K | ★ 2.2M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ 86.85 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $604,535,000.00 | N/A |
| Revenue This Year | $8.57 | N/A |
| Revenue Next Year | $10.59 | N/A |
| P/E Ratio | $110.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $216.57 | $14.00 |
| 52 Week High | $363.89 | $27.31 |
| Indicator | SXI | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 41.96 |
| Support Level | N/A | $14.43 |
| Resistance Level | $269.42 | $19.48 |
| Average True Range (ATR) | 11.55 | 0.93 |
| MACD | -0.98 | -0.17 |
| Stochastic Oscillator | 0.46 | 8.54 |
Standex International Corp is a diversified industrial manufacturer with multiple products and services that are used in diverse commercial and industrial markets. The Company operates in four broad business segments: Electronics, Aerospace & Defense (A&D), Scientific, and Engraving & Hydraulics. The Electronics segment generates maximum revenue and is engaged in manufacturing and selling electronic components for applications throughout the end-user market spectrum. The Company has operations in the United States, Europe, Canada, Japan, Singapore, Mexico, Turkey, India, and China. The Company generates maximum revenue from the United States.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.